{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:07:29Z","timestamp":1791198449792,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd008141","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2010,12,8]],"date-time":"2010-12-08T00:00:00Z","timestamp":1291766400000}}],"reference-count":66,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008141.pub2","type":"journal-article","created":{"date-parts":[[2010,11,29]],"date-time":"2010-11-29T14:55:00Z","timestamp":1291042500000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Second-generation antipsychotics for obsessive compulsive disorder"],"prefix":"10.1002","author":[{"given":"Katja","family":"Komossa","sequence":"first","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; Moehlstrasse 26 M\u00fcnchen Germany 81675"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M","family":"Depping","sequence":"additional","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; Moehlstrasse 26 M\u00fcnchen Germany 81675"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Meyer","sequence":"additional","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; Moehlstrasse 26 M\u00fcnchen Germany 81675"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Kissling","sequence":"additional","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; Moehlstrasse 26 M\u00fcnchen Germany 81675"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[{"name":"Technische Universit\u00e4t M\u00fcnchen Klinikum rechts der Isar; Klinik und Poliklinik f\u00fcr Psychiatrie und Psychotherapie; Moehlstrasse 26 M\u00fcnchen Germany 81675"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,12,8]]},"reference":[{"key":"10.1002\/14651858.CD008141.pub2-BIB0001|cit1","unstructured":"Bystritsky A Ackerman DL Rosen RM Vapnik T Gorbis E Maidment KM Augmentation of SSRI response in refractory OCD using adjunct olanzapine: A placebo-controlled trial 154th Annual Meeting of the American Psychiatric Association; May 5-10; New Orleans; LA, NR636 Arlington, VA American Psychiatric Association 2001"},{"key":"10.1002\/14651858.CD008141.pub2-BIB0002|cit2","unstructured":"Bystritsky A Ackerman DL Rosen RM Vapnik T Gorbis E Maidment KM Augmentation of SSRI response in refractory OCD using adjunctive olanzapine: A placebo-controlled trial 39th Annual Meeting of the American College of Neuropsychopharmacology. 2000; Dec 10-14; San Juan; Puerto Rico,177 Nashville, TN American College of Neuropsychopharmacology 2000"},{"issue":"4","key":"10.1002\/14651858.CD008141.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"565","DOI":"10.4088\/JCP.v65n0418","article-title":"Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial","volume":"65","author":"Bystritsky","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD008141.pub2-BIB0004|cit4","first-page":"1","article-title":"Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study","volume":"5","author":"Carey","year":"2005","journal-title":"BMC Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD008141.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/YIC.0b013e32801182f7","article-title":"Effects of quetiapine on cognitive functioning in obsessive-compulsive disorder","volume":"22","author":"Geus","year":"2007","journal-title":"International Clinical Psychopharmacology"},{"issue":"8","key":"10.1002\/14651858.CD008141.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.4088\/JCP.v65n0803","article-title":"A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors","volume":"65","author":"Denys","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD008141.pub2-BIB0007|cit7","unstructured":"Denys D Van Megen H Wessenberg N Goldfein J A double-blind, placebo-controlled study of quetiapine addition in treatment refractory patients with OCD resistant to serotonin reuptake inhibitors 156th Annual Meeting of the American Psychiatric Association, May 17-22, San Francisco CA, P. 248 Arlington, VA American Psychiatric Association 2003"},{"key":"10.1002\/14651858.CD008141.pub2-BIB0008|cit8","unstructured":"Denys D Van Megen H Westenberg H A double-blind, placebo-controlled study of quetiapine addition in treatment refractory patients with OCD 156th Annual Meeting of the American Psychiatric Association, May 17-22, San Francisco CA, NR770 Arlington, VA American Psychiatric Association 2003"},{"key":"10.1002\/14651858.CD008141.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.euroneuro.2004.04.004","article-title":"Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study","volume":"15","author":"Ezegovesi","year":"2005","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008141.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00004850-200507000-00005","article-title":"Adding Quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study","volume":"20","author":"Fineberg","year":"2005","journal-title":"International Cinical Psychopharmacology"},{"key":"10.1002\/14651858.CD008141.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1017\/S1461145703003730","article-title":"Risperidone augmentation in treatment resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study","volume":"6","author":"Hollander","year":"2003","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008141.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/JCP.0b013e318185e735","article-title":"Quetiapin addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder","volume":"28","author":"Kordon","year":"2008","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008141.pub2-BIB0013|cit13","first-page":"132","article-title":"Adjunctive risperidone in the treatment of SSRI-refractory obsessive-compulsive disorder","volume":"5","author":"Baxter","year":"2002","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD008141.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"736","DOI":"10.4088\/JCP.v66n0610","article-title":"Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: A crossover study","volume":"66","author":"Li","year":"2005","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD008141.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1001\/archpsyc.57.8.794","article-title":"A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake-inhibitor-refractory obsessive-compulsive disorder","volume":"57","author":"McDougle","year":"2000","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008141.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.biopsych.2003.11.010","article-title":"A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder","volume":"550","author":"Shapira","year":"2004","journal-title":"Biological Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD008141.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.4088\/JCP.08m04269","article-title":"Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled study of 76 patients","volume":"70","author":"Vulink","year":"2009","journal-title":"Journal of Clinical Psychiatry online publication"},{"issue":"3","key":"10.1002\/14651858.CD008141.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/00004850-200205000-00004","article-title":"Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study","volume":"17","author":"Atmaca","year":"2002","journal-title":"International Clinical Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD008141.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0278-5846(03)00050-2","article-title":"Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder","volume":"27","author":"D'Amico","year":"2003","journal-title":"Progress in Neuropsychopharmacology and Biological Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD008141.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"700","DOI":"10.4088\/JCP.v63n0807","article-title":"Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study","volume":"63","author":"Denys","year":"2002","journal-title":"Journal of Clinical Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD008141.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"514","DOI":"10.4088\/JCP.v61n0709","article-title":"Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder","volume":"61","author":"Koran","year":"2000","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD008141.pub2-BIB0022|cit22","first-page":"17","article-title":"Comparative analysis of risperidone combining with paroxetine in treatment of obsessive compulsive disorder","volume":"15","author":"Liu","year":"2005","journal-title":"Journal of Clinical Psychological Medicine"},{"issue":"5","key":"10.1002\/14651858.CD008141.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.euroneuro.2008.01.001","article-title":"8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder","volume":"18","author":"Maina","year":"2008","journal-title":"European Neuropsychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD008141.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"863","DOI":"10.4088\/JCP.08m04369","article-title":"A long term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI refractory obsessive compulsive disorder","volume":"70","author":"Matsunaga","year":"2009","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD008141.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00004850-200201000-00006","article-title":"Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder","volume":"17","author":"Mohr","year":"2002","journal-title":"International Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD008141.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00004714-199202000-00003","article-title":"A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder","volume":"12","author":"Pigott","year":"1992","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD008141.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4088\/JCP.v58n0306","article-title":"Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders","volume":"58","author":"Stein","year":"1997","journal-title":"Journal of Clinical Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD008141.pub2-BIB0028|cit28","first-page":"402","article-title":"A comparative study on the efficacy of combining risperidone and fluoxetine in the treatment of refractory obsessive compulsive disorder","volume":"11","author":"Yang","year":"2002","journal-title":"Chinese Journal of Behavioural Medical Science"},{"key":"10.1002\/14651858.CD008141.pub2-BIB0029|cit29","unstructured":"Diniz J B Using drug augmentation to treat obsessive compulsive disorder patients who did not respond to previous treatment (EPMTOC) http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00466609 may 2007"},{"key":"10.1002\/14651858.CD008141.pub2-BIB0030|cit30","unstructured":"Simpson B Foa E Risperidone or cognitive-behavioral therapy for improving medication treatment for obsessive-compulsive disorder http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00389493 2006"},{"key":"10.1002\/14651858.CD008141.pub2-BIB0031|cit31","unstructured":"Storch E Mutch J Double blinded, placebo-controlled trial of paliperidone addition in SRI-resistant obsessive-compulsive disorder http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00632229 2007"},{"issue":"11","key":"10.1002\/14651858.CD008141.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","article-title":"Antipsychotic-induced weight gain: a comprehensive research synthesis","volume":"156","author":"Allison","year":"1999","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008141.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewedness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD008141.pub2-BIB0034|cit34","volume-title":"Diagnostic and Statistical Manual of Mental Disorders, Third Edition (DSM III)","author":"American Psychiatric Association","year":"1980"},{"key":"10.1002\/14651858.CD008141.pub2-BIB0035|cit35","volume-title":"Diagnostic and Statistical Manual of Mental Disorders, 3rd edition- Revised (DSM-III-R)","author":"American Psychiatric Association","year":"1987"},{"key":"10.1002\/14651858.CD008141.pub2-BIB0036|cit36","volume-title":"Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV)","author":"American Psychiatric Association","year":"1994"},{"key":"10.1002\/14651858.CD008141.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0893-133X(97)00112-7","article-title":"Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence","volume":"18","author":"Arnt","year":"1998","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008141.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD008141.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/sj.mp.4001823","article-title":"A systematic review: antipsychotic augmentation with treatment refractory obsessive compulsive disorder","volume":"11","author":"Bloch","year":"2006","journal-title":"Molecular Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD008141.pub2-BIB0040|cit40","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006531","article-title":"Paroxetine versus other anti-depressive agents for depression","author":"Cipriani","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008141.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1176\/appi.ajp.161.3.414","article-title":"Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of one-year studies","volume":"161","author":"Correll","year":"2004","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD008141.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"Der-Simonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD008141.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD008141.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD008141.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analysis can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"issue":"11","key":"10.1002\/14651858.CD008141.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1001\/archpsyc.1989.01810110054008","article-title":"The Yale-Brown Obsessive Compulsive Scale: Development, use and reliability","volume":"46","author":"Goodman","year":"1989","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008141.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.euroneuro.2009.04.003","article-title":"Advantages and disadvantages of combination treatment with antipsychotics ECNP consensus Meeting, March 2008, Nice","volume":"19","author":"Goodwin","year":"2009","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008141.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intra class correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD008141.pub2-BIB0049|cit49","volume-title":"Clinical Global Impressions - ECDEU Asessment Manual Psychopharmacology (DHEW Publ No ADM 76-338)","author":"Guy","year":"1976"},{"key":"10.1002\/14651858.CD008141.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating","volume":"32","author":"Hamilton","year":"1959","journal-title":"British Journal of Medical Psychology"},{"key":"10.1002\/14651858.CD008141.pub2-BIB0051|cit51","first-page":"56","article-title":"A rating scale of depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"Journal of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD008141.pub2-BIB0052|cit52","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005170.pub2","article-title":"Pharmacotherapy for anxiety disorders in children and adolescents","author":"Hawkridge","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008141.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1176\/appi.ajp.163.2.185","article-title":"Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine","volume":"163","author":"Heres","year":"2006","journal-title":"American Journal of Psychiatry"},{"issue":"7414","key":"10.1002\/14651858.CD008141.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD008141.pub2-BIB0055|cit55","doi-asserted-by":"crossref","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008] The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org 2008","DOI":"10.1002\/9780470712184"},{"issue":"4","key":"10.1002\/14651858.CD008141.pub2-BIB0056|cit56","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005473.pub2","article-title":"Pharmacotherapy augmentation strategies in treatment resistant augmentation disorders","author":"Ipser","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008141.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1017\/S0954579408000606","article-title":"The neural base of obsessive compulsive disorder in children and adults","volume":"20","author":"Maia","year":"2008","journal-title":"Development and Psychopathology"},{"issue":"15","key":"10.1002\/14651858.CD008141.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.285.15.1987","article-title":"The CONSORT Statement: revised recommendations for improving the quality of reports of parallel-group randomized trials","volume":"285","author":"Moher","year":"2001","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD008141.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"British Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD008141.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.pnpbp.2005.11.028","article-title":"Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines","volume":"30","author":"Pallanti","year":"2006","journal-title":"Progress in Neuropsychopharmacology and Biological Psychiatry"},{"issue":"11","key":"10.1002\/14651858.CD008141.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1517\/14656566.8.11.1693","article-title":"Novel uses for risperidone: focus on depressive, anxiety and behavioral disorders","volume":"8","author":"Ravindran","year":"2007","journal-title":"Expert Opinion in Pharmacotherapy"},{"key":"10.1002\/14651858.CD008141.pub2-BIB0062|cit62","first-page":"no page numbers","article-title":"The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication","volume":"epub ahead of p","author":"Ruscio","year":"2008","journal-title":"Molecular Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD008141.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s11920-003-0062-9","article-title":"Treatment for mood and anxiety disorders: quetiapine and aripiprazole","volume":"5","author":"Sajatovic","year":"2003","journal-title":"Current Psychiatry Reports"},{"key":"10.1002\/14651858.CD008141.pub2-BIB0064|cit64","first-page":"1","article-title":"Seroquel led antipsychotics sales in 2006","volume":"35","author":"Vital","year":"2007","journal-title":"Clinical Psychiatric News"},{"key":"10.1002\/14651858.CD008141.pub2-BIB0065|cit65","volume-title":"International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10)","author":"World Health Organization","year":"1992"},{"key":"10.1002\/14651858.CD008141.pub2-BIB0066|cit66","article-title":"Epidemiology, comorbidity and course of obsessive compulsive disorder","volume-title":"Obsessive Compulsive Disorder: Diagnosis and Treatment [Die Zwangsst\u00f6rung: Diagnostik und Therapie]","author":"Zaudig","year":"2002"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD008141.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,4]],"date-time":"2023-06-04T05:32:22Z","timestamp":1685856742000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD008141.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Common Mental Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2010,12,8]]},"references-count":66,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008141.pub2","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718508459.793497752","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,8]]}}}